Navigation Links
Aratana Therapeutics Appoints Craig Tooman to Board of Directors
Date:5/9/2012

KANSAS CITY, Kan. and NEW YORK, May 9, 2012 /PRNewswire/ -- Aratana Therapeutics, an animal health company developing innovative medicines for companion animals, has announced the appointment of Craig Tooman, to its Board of Directors.

During his distinguished career, Mr. Tooman has held various senior positions in the pharmaceutical industry in international finance, sales, market research, business intelligence, strategic business management, and investor relations. After nearly a decade with Pharmacia & Upjohn (now Pfizer), Mr. Tooman moved to the biotechnology industry.

Mr. Tooman has made substantial contributions to companies including Ilex Oncology, which was sold to Genzyme Corporation for $1.1 billion; Enzon Pharmaceuticals and Ikaria.  Mr. Tooman has recently been appointed CEO of Avanzar Medical, and he has been named entrepreneur-in-residence by the Cancer Prevention and Research Institute of Texas.

"Craig's exceptional track record guiding the evolution of different types of life sciences companies, his experience not just with finance but with all the disciplines that create a company's growth potential, and his ability to communicate with the financial community are skills Aratana will draw on extensively as we continue to develop new medicines to address unmet needs in companion animal health," says Board of Directors Chair Dr. Steven St. Peter.

Mr. Tooman has a Bachelor of Arts degree in economics with a minor in Japanese Language and a concentration in International Finance from Kalamazoo College. He received his MBA in Finance from the University of Chicago.

"Aratana's business model is unique and compelling in the animal health industry, and I believe the team guiding the company is exceptional," Mr. Tooman says. "I look forward to serving on the Board of Directors and helping shape the future of this very exciting enterprise."

About Aratana Therapeutics

Aratana Therapeutics is an animal health drug development company uniquely positioned to deliver high quality new medicines for unmet needs in animal health. Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then out-licenses to or partners with major animal health companies for commercialization. For more information, please visit www.aratanatherapeutics.com.

Contact: Dr. Linda Rhodes, CEO (lrhodes@aratanarx.com), 732-895-5420


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aratana Therapeutics Announces $20 Million Financing
2. Aratana Therapeutics Completes $15 Million Series B Financing
3. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
4. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
5. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
6. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
7. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
8. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
9. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
10. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
11. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 2016   ViaCyte, Inc ., a leading, ... stem cell-derived islet replacement therapy for the treatment ... announced that ViaCyte and Janssen Biotech, Inc., one ... Johnson, have agreed to consolidate the assets of ... provides ViaCyte with an exclusive license to all ...
(Date:2/3/2016)... -- With the growing need for better therapeutics, and ... such as monoclonal antibodies, recombinant protein therapeutics and ... are in high demand. Conventionally expression systems were ... of these therapeutics. However, due to issues with ... approaches and novel expression systems are currently being ...
(Date:2/3/2016)... Mass., Feb. 3, 2016 Harvard Apparatus ... biotechnology company developing bioengineered organ implants for life-threatening ... announced that CEO Jim McGorry , will ... Conference on Tuesday, February 9, 2016 at ... City . HART,s presentation will be webcast ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, ... office dedicated to the North American healthcare market. , Aerocom Healthcare, LLC will ... The company will provide new pneumatic tube systems or expand existing systems ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 4, 2016 --> ... to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of ... amounted to SEK 517.6 M (loss: 30.0). Earnings per share ... activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... analysis of the bioinformatic market by reviewing the ... computer enabled tools that drive the field forward. ... report to: Identify the challenges and opportunities ... service providers and software solution developers, as well ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):